Abstract
PURPOSE: US regulatory authorities recently approved the use of once-daily mometasone furoate administered via a dry powder inhaler (MF-DPI) for treatment of asthma in children ages 4–11 years. Using data from a pediatric clinical trial that demonstrated the efficacy of MF-DPI used once daily in the evening (QD PM), we investigated the time to onset of a significant therapeutic effect.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
